Amgen (AMGN)
272.44
-16.89 (-5.84%)
NASDAQ · Last Trade: Jun 23rd, 11:28 PM EDT
Detailed Quote
Previous Close | 289.33 |
---|---|
Open | 290.08 |
Bid | 274.00 |
Ask | 274.49 |
Day's Range | 267.83 - 290.66 |
52 Week Range | 253.30 - 346.85 |
Volume | 5,764,914 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 9.520 (3.49%) |
1 Month Average Volume | 2,965,264 |
Chart
About Amgen (AMGN)
Amgen is a leading biotechnology company that focuses on the development, manufacturing, and commercialization of innovative therapeutic solutions to treat serious illnesses. The company leverages its advanced science and research capabilities to create biologic therapies that target various medical conditions, including cancer, kidney disease, and rheumatoid arthritis. Through a commitment to scientific excellence, Amgen aims to enhance patient care by providing effective treatments that improve health outcomes and quality of life. Additionally, the company engages in extensive research collaborations and partnerships, further advancing its mission to deliver groundbreaking therapies to patients around the world. Read More
News & Press Releases
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of MariTide.
Via Benzinga · June 23, 2025
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via Chartmill · June 23, 2025
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.
Via Investor's Business Daily · June 23, 2025
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
Via Benzinga · June 20, 2025
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Via StockStory · June 20, 2025
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such as Ireland and Bermuda, according to CNBC.
Via Stocktwits · June 17, 2025
Via The Motley Fool · June 17, 2025
The company is progressing with multiple Phase 2 trials for its investigational treatment targeting severe respiratory diseases.
Via Stocktwits · June 15, 2025
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide.
Via Investor's Business Daily · June 6, 2025

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Via StockStory · June 4, 2025

The company also stated that the interim data from the trial showed the therapy significantly extended median overall survival by more than five months.
Via Stocktwits · June 2, 2025

The Dow Jones (^DJI) is made up of 30 of the most established and influential companies in the market.
But even blue-chip stocks can struggle - some are dealing with slowing growth, outdated business models, or increasing competition.
Via StockStory · May 29, 2025
The race to quantum supremacy is on. While this future will not come tomorrow, big tech companies are building to the technology's "ChatGPT moment."
Via The Motley Fool · May 27, 2025
Via The Motley Fool · May 27, 2025
Via The Motley Fool · May 24, 2025
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.
Via The Motley Fool · May 24, 2025
The company is working on an Alzheimer's treatment that increases the activity of TREM2, a neuroinflammation target.
Via Investor's Business Daily · May 22, 2025
Marjorie Taylor Greene disclosing buying 19 different stocks in a new filing. The buys come less than two weeks after the purchase of 50 different stocks.
Via Benzinga · May 20, 2025